Real World Evidence Is Critical To Pharma’s Future: Can We Agree On What It Is?

Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.

A group of people in the shape of tag, medicine, flash mob.
Industry is eager for more practical data on real world use of medicines. • Source: Shutterstock: tai11

Real world evidence is of huge strategic importance to the pharmaceutical industry. It is critical to demonstrating the value of existing products, and to developing new ones that effectively address patients’ needs. It is the key to a more efficient, sustainable health system. Sources of real world evidence are proliferating as technology and data analytics tools invade the health care space. This kind of data must feature prominently, and early, in product evidence plans.

Yet no one agrees on exactly what “real world evidence” is. There is no consensus on the validity of real world evidence – which comes in multiple forms – nor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

 
• By 

Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.